# Benzothiazepine derivatives.

## Abstract
Vasodilating activity is exhibited by new compounds having the formula

## Claims
1. A compound having the formula or such a compound in pharmaceutically acceptable salt form, wherein n is 2 or 3 X is oxygen or sulfur R₁ and R₂ are each independently hydrogen, alkyl, cycloalkyl, or allyl, or R₁ and R₂ together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl R₃ is alkyl, alkoxy, halogen, trifluoro methyl, or nitro R₄ is hydrogen, halogen, or trifluoromethyl, or nitro and R₅ and R₆ are each independently alkyl or cycloalkyl or R₅ and R₆ together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl.

## Description
The present invention relates to new compounds having the formula The terms alkyl and alkoxy refer to both straight and branched chain groups. R groups having 1 to 10 carbon atoms are preferred. The term halogen refers to fluorine, chlorine, bromine and iodine. The compounds of formula I form acid addition salts with inorganic and organic acids. These acid addition salts frequently provide useful means for isolating the products from reaction mixtures by forming the salt in a medium in which it is insoluble. The free base may then be obtained by neutralization, The carbon atoms in the 2 and 3 positions of the benzothiazepine nucleus of the compounds of formula I are asymmetric carbons. The compounds of formula I, therefore, exist in stereoisomeric forms and as racemic mixtures thereof. This invention is directed to those compounds of formula I which have been described above, wherein the stereochemistry at the chiral centers in the 2 and 3 positions of the benzothiazepine nucleus is d cis. The compounds of formula I, and the pharmaceutically acceptable salts thereof, are useful as cardiovascular agents. These compounds act as vasodilators and are useful as anti hyper tensive agents. By the administration of a composition containing one or a combination of the compounds of this invention the blood pressure of a hypertensive mammalian As a result of the vasodilating activity of the compounds of formula I, it is believed that such compounds in addition to being anti hyper tensives may also be useful as antiarrhythmic agents, as anti anginal agents, as anti fibrillatory agents, as anti asthmatic agents, and in limiting myocardial infarction. The compounds of this invention can also be formulated in combination with a diuretic, or a beta adrenergic agent, or angiotensin converting enzyme inhibitor. Suitable diuretics include the thiazide diuretics such as hydrochlorothiazide and bendroflumethiazide, suitable beta adrenergic agents include nadolol, and suitable angiotensin converting enzyme inhitibors include captopril. The compounds of formula I can be prepared by first reacting a compound having the formula An alternative method for preparing the compounds of formula I wherein one of R₁ and R₂ is hydrogen comprises reacting a compound of formula II or its sodium salt, with an isocyanate or iso thiocyanate having the formula V R₁N C X in an inert organic solvent An alternative method for preparing the compounds of formula I wherein neither R₁ nor R₂ is hydrogen comprises reacting a compound of formula II, preferably as a sodium salt, with a compound having the formula The starting benzothiazepines of formula II are readily obtainable utilizing prior art method ology see, for example, United States patent 3,562,257 and Chem. Pharm. Bull., The following examples are specific embodiments of this invention. d cis 5 2 Dimethylamino ethyl 2,3 dihydro 3 hydroxy 2 4 methoxyphenyl 1,5 benzo thiazepin 4 5H one 4.17 g was dissolved in 25 ml of acetonitrile, stirred and treated dropwise with 6.4 g 111 mmol of methyl isocyanate. After stirring for 24 hours at room temperature, the solution was concentrated on a rotary evaporator to give 5.13 g of a solid. This material was dissolved in 100 ml of ethyl acetate, extracted twice with 10 ml of water, dried magnesium sulfate , filtered and the solvent evaporated to give 4.93 g of a foam like solid. After two recrystallizations from 25 ml iso propanol 100 ml hexane, the material weighed 4.07 g, melting point 76 79 C, α In these examples, optical rotations were determined on 1 solutions in methanol at room temperature. Analysis Calc d for C₂₂H₂₇N₃O₄S isopropanol C, 61.33 H, 7.21 N, 8.58 S, 6.55 Found C, 61.31 H, 7.23 N, 8.44 S, 6.58 The above solvate 4.0 g was dissolved in 25 ml of warm ethanol, cooled and treated with 1.40 ml of 6.0 N hydrogen chloride in ethanol. The resulting solution was diluted with 75 ml of ether to give an oily product which rapidly became granular. After cooling for 3 hours, the solid was filtered and dried 3.81 g , melting point 195 197 C, α Dilution of the above filtrate to 150 ml with ether gave an additional 0.47 g of colorless product, melting point 194 196 C dec. . Analysis Calc d for C₂₂H₂₇N₃O₄S HCl C, 56.70 H, 6.06 N, 9.02 S, 6.88 Cl, 7.60 Found C, 56.68 H, 6.12 N, 8.98 S, 6.84 Cl, 7.42 To a solution of 4.1 g of d cis 5 2 dimethylamino ethyl 2,3 dihydro 3 hydroxy 2 4 methoxyphenyl 1,5 benzothiazepin 4 5H one in 25 ml of acetonitrile was added 7.8 g 110 mmol of ethyl isocyanate portionwise. After standing for 20 hours at room temperature, the solvent was removed on a rotary evaporator to give 5.1 g of a colorless foam like residue. The material was dissolved in 25 ml of acetonitrile, treated portionwise with 1.8 ml of 6N hydrogen chloride in ethanol and the resulting solution gradually diluted with 100 ml of ether. The hydrochloride salt initially separated as an oil then changed to a granular colorless solid. After cooling overnight, the solid was filtered to give 4.2 g of product, melting point 187 190 C. α A solution of 4.2 g of d cis 5 2 dimethyl amino ethyl 2,3 dihydro 3 hydroxy 2 4 methoxy phenyl 1,5 benzothiazepin 4 5H one in 25 ml of chloroform was added at 4 6 C with stirring to 12 ml of 12.5 phosgene in benzene dissolved in 25 ml of chloroform a solid separated soon after the addition was begun. After the addition, the mixture was allowed to warm to room temperature to give a yellow solution. After 5 hours, 3 ml more of phosgene solution was added and stirring was continued overnight. After passing in nitrogen to remove excess phosgene, the solvent was removed on a rotary evaporator to give 6.2 g of the title compound as a yellow brittle solid. A stirred solution of d cis 3 chloro formyl oxy 5 2 dimethylamino ethyl 2,3 dihydro 2 4 methoxyphenyl 1,5 benzothiazepin 4 5H one, monohydrochloride 6.2 g 0.011 mol in 60 ml of dichloromethane was cooled in ice water and ammonia was passed in for 30 minutes. After the addition of ammonia, the mixture was allowed to warm gradually to room temperature and to stir overnight. The mixture was placed on a rotary evaporator and the bulk of solvent was removed. The yellow foamy residue was stirred with 50 ml of ethyl acetate and 20 ml of water and basified with 2 g of potassium carbonate. The layers were separated and the aqueous phase was extracted three times with ethyl acetate 25 ml . The combined organic layers were washed with saturated sodium chloride 25 ml dried magnesium sulfate , and the solvent evaporated to give 4.4 g of a yellow fluffy amorphous solid. The material was taken up in 20 ml of acetonitrile. On seeding and rubbing, a solid gradually separated. After cooling overnight, the nearly colorless solid was filtered, washed with cold acetonitrile, and air dired yielding 1.0 g of material. Following recrystallization of 0.97 g of product from 9 ml of hot isopropanol 12 ml of hexane, the colorless product weighed 0.87 g, melting point 179 181 C, α A suspension of d cis 5 2 dimethyl amino ethyl 2,3 dihydro 2 4 methoxyphenyl 3 aminocarbonyl oxy 1,5 benzothiazepin 4 5H one 0.83 g in 10 ml of acetonitrile was treated with 0.35 ml of 6N ethanolic hydrogen chloride to give a solution. After evaporating the solvent, the semi solid residue was taken up in 3 ml of acetonitrile, warmed slightly and diluted with several volumes of ether to precipitate the solid hydrochloride salt. After cooling overnight, the colorless product was filtered under argon, washed with ether, and dried A stirred solution of 3.37 g 9.05 mmol of d cis 5 2 dimethylamino ethyl 2,3 dihydro 3 hydroxy 2 4 methoxyphenyl 1,5 benzothiazepin 4 5H one 3.,37 g, 9.05 mmol in 120 ml of benzene was treated with 0.7 g 14.6 mmol of 50 sodium hydride oil dispersion and heated to reflux for 1 hour. The yellow orange solution was cooled to 30 C, freshly distilled dimethylcarbamyl chloride 0.95 ml, 10.3 mmol was added, and the mixture was stirred at room temperature. After stirring overnight, 120 ml of ether was added, followed by 1.4 g of potassium carbonate in 35 ml of water. The layers were separated, the organic phase washed with 35 ml of water and 35 ml of saturated sodium chloride solution, dried magnesium sulfate , and the solvents evaporated to give 4.1 g of a yellow orange syrup. The crude base was combined with 1.0 g of base from an earlier experiment by dissolving in 30 ml of methanol, treated with 1.33 g of fumaric acid, warmed slightly to obtain a solution, and diluted to 250 ml with ether. On seeding and rubbing, the solid salt rapidly separated. After cooling overnight, the cream colored solid was filtered, washed with ether, and dried Utilizing the procedure of Example 1, but substituting an equivalent quantity of isopropyl isocyanate for the methyl isocyanate, yields the title product. Utilizing the procedure of Example 1, but substituting cyclopropyl isocyanate for the methyl isocyanate, yields the title product. Utilizing the procedure of Example 1, but substituting cyclohexyl isocyanate for the methyl iscoyanate, yields the title product. Utilizing the procedure of Example 1, but substituting allyl isocyanate for the methyl isocyanate, yields the title product. Utilizing the procedure of Example 3, but substituting two equivalents of piperidine for the ammonia in part B, yields the title product. Utilizing the procedure of Example 3, but substituting two equivalents of morpholine for the ammonia in part B, yields the title product. Utilizing the procedure of Example 4, but substituting diethylcarbamyl chloride for the dimethylcarbamyl chloride, yields the title product. Utilizing the procedure of Example 4, but substituting 5 equivalents of methyl isothiocyanate for the dimethylcarbamyl chloride, yields the title product. Utilizing the procedure of Example 4, but substituting 5 equivalents of n propyl isothio cyanate for the dimethylcarbamyl chloride, yields the title product. Utilizing the procedure of Example 4, but substituting 5 equivalents of t butyl isothio cyanate for the dimethylcarbamyl chloride, yields the title product. Utilizing the procedure of Example 3, but substituting thiophosgene for the phosgene in part A, yields the title product. Utilizing the procedure of Example 3, but substituting thiophosgene for the phosgene in part A and then replacing the ammonia with two equivalents of dimethylamine, yields the title product. The reaction of d cis 5 2 dimethyl amino ethyl 2,3 dihydro 3 hydroxy 2 4 methyl phenyl 1,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the method described in Example 1 yields the title product. The reaction of d cis 5 2 dimethylamino ethyl 2,3 dihydro 2 4 chlorophenyl 3 hydroxy 2,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the method described in Example 1 yields the title product. The reaction of d cis 5 2 dimethylamino ethyl 2,3 dihydro 2 4 methoxyphenyl 3 hydroxy 8 chloro 1,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the method described in Example 1 yields the title product. The reaction of d cis 5 2 dimethylamino ethyl 2,3 dihydro 2 4 methoxyphenyl 3 hydroxy 8 trifluoromethyl 1,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the procedure described in Example 1 yields the title product. The reaction of d cis 5 2 dimethylamino ethyl 2,3 dihydro 2 4 methoxyphenyl 3 hydroxy 7 trifluoromethyl 1,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the procedure described in Example 1 yields the title product. The reaction of d cis 5 3 dimethylamino propyl 2,3 dihydro 2 4 methoxyphenyl 3 hydroxy 1,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the procedure described in Example 1 yields the title product. The reaction of d cis 5 2 piperidino ethyl 2,3 dihydro 2 4 methoxyphenyl 3 hydroxy 1,5 benzothiazepin 4 5H one with 5 equivalents of methyl isocyanate in acetonitrile according to the procedure described in Example 1 yields the title product.